Vascular GLP‐1 receptor, a target of T2D‐therapy, and TCF7L2 expression were significantly downregulated in obese subjects, indicating that TCF7L2 modulates vascular GLP‐1 receptor expression (Kimura et al., 2018). This evidence concerns the gene TCF7L2 and type 2 diabetes mellitus.